Skip links
Chandon Alexander

Nevada Pharmacy Board Investigation Defense: Your Legal Guide

A letter or phone call from the Nevada State Board of Pharmacy can change the trajectory of your entire career. Whether you are a pharmacist, pharmacy technician, or pharmacy owner, a board investigation represents a direct threat to your professional license, your livelihood, and in

Read More »
Chandon Alexander

FDA Category 1 vs Category 2 Peptides Explained

The FDA’s classification system for compounded peptides has become one of the most consequential regulatory frameworks in healthcare, yet most providers who prescribe or dispense these substances do not fully understand how it works. That knowledge gap is creating serious legal exposure. Providers are making

Read More »
Chandon Alexander

Board Investigator Response Guide: Steps to Take Now

You just received a phone call, a letter, or an email from a board investigator. The message references your prescribing practices, your use of peptides, or a complaint filed against your license. Your stomach dropped. You are reading this because you need to know what

Read More »
Chandon Alexander

RUO Peptides Won’t Protect Your Practice

If you are selling, prescribing, or distributing peptides labeled “For Research Use Only,” you may believe that label creates a legal barrier between your business and the FDA. It does not. The FDA has made clear, through enforcement actions, federal prosecutions, and public guidance, that

Read More »
Chandon Alexander

GLP-1 Compounding Legal Risks for Pharmacies & Clinics

The compounded GLP-1 market exploded over the past three years, driven by massive consumer demand for weight loss medications, brand-name supply shortages, and the price gap between compounded formulations and FDA-approved products like Ozempic, Wegovy, Mounjaro, and Zepbound. At its peak, hundreds of compounding pharmacies,

Read More »
Chandon Alexander

Can You Still Compound BPC-157 in 2026?

If you are a compounding pharmacy, prescribing physician, or clinic operator who has been watching the regulatory landscape around BPC-157, the past twelve months have been defined by confusion. Headlines announcing that the FDA removed BPC-157 from its Category 2 list in April 2026 created

Read More »
Chandon Alexander

7 Peptides Face FDA Review in July 2026. Is Your Practice Exposed?

On June 29, 2026, the FDA’s career scientists posted briefing documents for the upcoming Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23 and 24. In each document, the agency recommended against easing restrictions on the peptides under review, concluding there was not enough

Read More »
Chandon Alexander

How Prior DUI Convictions Affect Your Current Case in Nevada

A second DUI arrest feels different from your first. The stakes are higher, the penalties are harsher, and prosecutors show far less leniency. If you’re facing DUI charges with prior convictions on your record, understanding how Nevada treats repeat offenders is essential to protecting yourself

Read More »
Chandon Alexander

Understanding Nevada’s Implied Consent Law for DUI Testing

Getting pulled over for suspected DUI puts you in a high-stakes situation where split-second decisions have lasting consequences. One of the most critical choices you face is whether to submit to chemical testing. Many drivers don’t realize that by simply driving on Nevada roads, you’ve

Read More »
Chandon Alexander

Can You Get a DUI Expunged in Nevada?

A DUI conviction follows you for years, appearing on background checks, affecting employment opportunities, and damaging your reputation. Many people assume DUI convictions remain on their records permanently. Fortunately, Nevada law allows DUI record sealing under specific circumstances and timelines. At Spartacus Law Firm, we

Read More »
HOME
REVIEWS
RESULTS
(702) 660-1234